Use of Amniotic Membrane May Cause Complications in Strabismus Surgery

Negative Outcome Reported in the Journal of AAPOS



Philadelphia, PA, January 3, 2011
– Postoperative adhesions are a major complication in strabismus surgery. Amniotic membrane has been used in the hopes of preventing these adhesions by forming a biological barrier during healing. In an article in the December 2010 issue of the Journal of AAPOS, the Official Publication of the American Association of Pediatric Ophthalmology and Strabismus, a team of researchers from Cairo University have discovered that the new approach may also have the opposite effect.

Dr. Rehab Kassem and coauthors describe how they wrapped the extraocular muscles with lyophilized amniotic membrane in a patient undergoing a strabismus reoperation on both medial rectus muscles. However, the surgical result was not optimal, and the patient underwent a fourth procedure that included exploration of the medial rectus muscles. Instead of finding less scarring, the surgeons found extensive adhesions and inelastic, fibrotic muscles.

Amniotic membrane may be fresh or preserved. Preserved amniotic membrane may be either frozen, air-dried, or freeze-dried. Frozen amniotic membrane is expensive and it must be stored at -80°C, thus limiting its availability. Dried amniotic membrane is less expensive and does not require special storage conditions.

The authors of the article speculate that their results may have been due to the use of dried, rather than frozen, amniotic membrane. Writing in the article, Rehab Kassem, MD, states, "What caused the fibrosis in our case? Was it related to the use of amniotic membrane or was it coincidental, perhaps the result of excessive dissection to achieve a large recession? If the former, then was the fibrosis related to the nature (lyophilized vs. cryopreserved) of the amniotic membrane used or to its possibly having been placed toward the sclera rather than the muscle? In conclusion, although the cause of the fibrosis in our case is not clear, lyophilized amniotic membrane was ineffective in protecting against its development."

"There are only a few reports of the use of amniotic membrane in extraocular muscle surgery, and the results of those studies are equivocal," says David G. Hunter, MD, PhD, Editor-in-Chief of the Journal of AAPOS. "While this material may have been used successfully in other parts of the eye, strabismus surgeons should only consider using it around extraocular muscles in cases where there is already extreme scarring, and not as a preventive measure, as was done here."

The article is “Severe fibrosis of extraocular muscles after the use of lyophilized amniotic membrane in strabismus surgery” by Rehab R. Kassem, MD, FRCS(Glasg), Ghada I. Gawdat, MD, and Rasha H. Zedan, MD. It appears in the Journal of AAPOS, Volume 14, Issue 6 (December 2010) published by Elsevier.

# # #

Notes For Editors
Full text of the article is available to journalists upon request; contact Rachael Zaleski at 215-239-3658,rachael.zaleski@elsevier.com to obtain a copy or to request an interview with the authors.

About The Journal Of Aapos ( http://www.journals.elsevierhealth.com/periodicals/ympa)
Journal of AAPOS presents expert information on children's eye diseases and on strabismus as it impacts all age groups. Major articles by leading experts in the field cover clinical and investigative studies, treatments, case reports, surgical techniques, descriptions of instrumentation, current concept reviews and new diagnostic techniques. The Journal is the official publication of the American Association for Pediatric Ophthalmology and Strabismus.

About The American Association For Pediatric Ophthalmology And Strabismus
The goals of the AAPOS, the American Association for Pediatric Ophthalmology and Strabismus are to advance the quality of children's eye care, support the training of pediatric ophthalmologists, support research activities in pediatric ophthalmology and advance the care of adults with strabismus. ( www.aapos.org)

About Elsevier
As a global leader in information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making for customers across the global research and health ecosystems.

In everything we publish, we uphold the highest standards of quality and integrity. We bring that same rigor to our information analytics solutions for researchers, health professionals, institutions and funders.

Elsevier employs 8,100 people worldwide. We have supported the work of our research and health partners for more than 140 years. Growing from our roots in publishing, we offer knowledge and valuable analytics that help our users make breakthroughs and drive societal progress. Digital solutions such as ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath support strategic research management, R&D performance, clinical decision support, and health education. Researchers and healthcare professionals rely on our 2,500+ digitized journals, including The Lancet and Cell; our 40,000 eBook titles; and our iconic reference works, such as Gray's Anatomy. With the Elsevier Foundation and our external Inclusion & Diversity Advisory Board, we work in partnership with diverse stakeholders to advance inclusion and diversity in science, research and healthcare in developing countries and around the world.

Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com.

Media Contact
Rachael Zaleski
+1 215-239-3658
rachael.zaleski@elsevier.com